Olaparib significantly delayed disease progression as firstline maintenance treatment in germline BRCAmutated metastatic pancreatic cancer

Olaparib significantly delayed disease progression as first-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer

Results from the Phase III POLO trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with olaparib vs. placebo. The safety and tolerability profile of olaparib was consistent with previous...

More From BioPortfolio on "Olaparib significantly delayed disease progression as first-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer"